RE:RE:RE:Beam Therapeutics Phase 1 CAR-T study placed on hold by FDATaken from the yahoo message board posted in January 2022 .. " .. those hedge funds and investment banks who unscrupulously trade in this stock have been notorious for using paid employees to bash away at the stock, its shareholders, and its management while wildly working the price and trading action to accumulate as much stock possible in advance of an acquisition."
The above referenced sentiment appears to still apply as those who sold off the stock in January/February, in their attempt to squeeze the shareholder in their zeal to get control of as much of the float as they could, will likely have to cover what they either sold and/or shorted now that M&A activity is being to ramp up with the recent developments surrounding preclinial compnies lie Trillium and now Beam Therapeutic.
The beginning was when Pfizer aquired the pre-clinical company Trillium Therpaeutics for USD$ 2.3 Billion and now we see the pre-clinical CAR-T company Beam Therapeutics trading at a market cap of USD$ 4.5 Billion. Beam traded today in excess of USD$ 61 pps notwithstanding Friday's negative news of its Phase 1 trial being rejected by the FDA for reasons of concern over the safety of the company's base editing technology which may fail to have the DNA "sew itself up" once edited. Not a good thing .... yet Beam Technologies still trades at USD$60+ pps.
Meanwhile ONCY's continues to be plagued by hedge fund and their clients manipulation. Undoubtedly ONCY's acquisition by one of the Big Pharma company's who have partnered with the company should cure that condition.